A study of more than 140,000 Medicare patients with rheumatoid arthritis found that those on any biologic drug were 17 percent less likely than those using only a traditional DMARD to have developed dementia.
A new study shows that lupus patients who need to take hydroxychloroquine can be reassured that it does not have a significant risk for serious heart toxicity.
Certain risk factors, like being younger, obese, or having enthesitis, were linked with greater delays in PsA diagnosis.
New research shows that use of hydroxychloroquine did not predict prolonged QTc, a key measure of heart rate.
New research sheds more light on the racial health disparities that exist in arthritis treatments.
Methotrexate, commonly used in inflammatory forms of arthritis such as rheumatoid and psoriatic arthritis, could be helpful for targeting local and systemic inflammation in osteoarthritis when conventional therapies are not.
The medication romosozumab may be more effective at boosting hip and spine bone density when it’s given before other kinds of drugs called antiresorptive medications.
Researchers say patients should be reassured that these common injections do not appear to cause progression of osteoarthritis.
New research shows there is a need for aggressive preventive care to decrease racial health disparities and improve outcomes for lupus patients.
The research shows that earlier bone density screening and osteoporosis therapies could be highly beneficial for at-risk men, who are underdiagnosed and undertreated.